PL374664A1 - Sole benzenosulfonianowe pochodnych 4-fluoro-2-cyjanopirolidyny - Google Patents
Sole benzenosulfonianowe pochodnych 4-fluoro-2-cyjanopirolidynyInfo
- Publication number
- PL374664A1 PL374664A1 PL03374664A PL37466403A PL374664A1 PL 374664 A1 PL374664 A1 PL 374664A1 PL 03374664 A PL03374664 A PL 03374664A PL 37466403 A PL37466403 A PL 37466403A PL 374664 A1 PL374664 A1 PL 374664A1
- Authority
- PL
- Poland
- Prior art keywords
- benzenesulfonate
- fluoro
- cyanopyrrolidine derivative
- cyanopyrrolidine
- derivative
- Prior art date
Links
- HHFUFGKACHWIAV-UHFFFAOYSA-N 4-fluoropyrrolidine-2-carbonitrile Chemical class FC1CNC(C#N)C1 HHFUFGKACHWIAV-UHFFFAOYSA-N 0.000 title 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 title 1
- 229940077388 benzenesulfonate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002249821 | 2002-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL374664A1 true PL374664A1 (pl) | 2005-10-31 |
Family
ID=31972599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03374664A PL374664A1 (pl) | 2002-08-29 | 2003-08-27 | Sole benzenosulfonianowe pochodnych 4-fluoro-2-cyjanopirolidyny |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7304166B2 (pl) |
| EP (1) | EP1535907A4 (pl) |
| JP (1) | JP3746063B2 (pl) |
| KR (1) | KR100582141B1 (pl) |
| CN (1) | CN1310885C (pl) |
| AU (1) | AU2003261748B2 (pl) |
| BR (1) | BR0313831A (pl) |
| CA (1) | CA2496623C (pl) |
| EA (1) | EA007613B1 (pl) |
| EC (1) | ECSP055708A (pl) |
| HK (1) | HK1082497A1 (pl) |
| HR (1) | HRP20050205A2 (pl) |
| MX (1) | MXPA05002253A (pl) |
| NO (1) | NO20050867L (pl) |
| NZ (1) | NZ538956A (pl) |
| PL (1) | PL374664A1 (pl) |
| UA (1) | UA78104C2 (pl) |
| WO (1) | WO2004020407A1 (pl) |
| ZA (1) | ZA200501418B (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US20080114053A1 (en) | 2005-01-27 | 2008-05-15 | Mitsui Chemicals, Inc. | Method for Producing Fluorinated Proline Derivative |
| JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
| EP1888571A2 (en) | 2005-03-22 | 2008-02-20 | F. Hoffmann-Roche AG | New salt and polymorphs of a dpp-iv inhibitor |
| ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| JP5616630B2 (ja) | 2007-04-03 | 2014-10-29 | 田辺三菱製薬株式会社 | ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
| AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4432987A (en) | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| TW486475B (en) | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
| JP3107784B2 (ja) | 1996-12-26 | 2000-11-13 | 宇部興産株式会社 | 光学活性ピペリジン誘導体の酸付加塩及びその製法 |
| US6252063B1 (en) | 1998-12-01 | 2001-06-26 | Merck & Co., Inc. | Crystalline salts of a carbapenem antibiotic |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
-
2003
- 2003-08-27 BR BR0313831-3A patent/BR0313831A/pt not_active IP Right Cessation
- 2003-08-27 CN CNB038203367A patent/CN1310885C/zh not_active Expired - Fee Related
- 2003-08-27 KR KR1020057003211A patent/KR100582141B1/ko not_active IP Right Cessation
- 2003-08-27 PL PL03374664A patent/PL374664A1/pl not_active Application Discontinuation
- 2003-08-27 CA CA002496623A patent/CA2496623C/en not_active Expired - Fee Related
- 2003-08-27 EA EA200500420A patent/EA007613B1/ru not_active IP Right Cessation
- 2003-08-27 EP EP03791325A patent/EP1535907A4/en not_active Withdrawn
- 2003-08-27 US US10/525,748 patent/US7304166B2/en not_active Expired - Fee Related
- 2003-08-27 NZ NZ538956A patent/NZ538956A/en unknown
- 2003-08-27 MX MXPA05002253A patent/MXPA05002253A/es active IP Right Grant
- 2003-08-27 AU AU2003261748A patent/AU2003261748B2/en not_active Ceased
- 2003-08-27 WO PCT/JP2003/010828 patent/WO2004020407A1/ja not_active Application Discontinuation
- 2003-08-27 JP JP2004532725A patent/JP3746063B2/ja not_active Expired - Fee Related
- 2003-08-27 UA UAA200502704A patent/UA78104C2/uk unknown
- 2003-08-27 ZA ZA200501418A patent/ZA200501418B/xx unknown
-
2005
- 2005-02-18 NO NO20050867A patent/NO20050867L/no not_active Application Discontinuation
- 2005-03-03 HR HR20050205A patent/HRP20050205A2/hr not_active Application Discontinuation
- 2005-03-28 EC EC2005005708A patent/ECSP055708A/es unknown
-
2006
- 2006-02-24 HK HK06102523A patent/HK1082497A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ538956A (en) | 2006-08-31 |
| HRP20050205A2 (en) | 2005-10-31 |
| UA78104C2 (en) | 2007-02-15 |
| ZA200501418B (en) | 2006-10-25 |
| EA007613B1 (ru) | 2006-12-29 |
| BR0313831A (pt) | 2005-07-05 |
| EP1535907A4 (en) | 2006-11-29 |
| EA200500420A1 (ru) | 2005-08-25 |
| CN1678575A (zh) | 2005-10-05 |
| CA2496623A1 (en) | 2004-03-11 |
| JPWO2004020407A1 (ja) | 2005-12-15 |
| US7304166B2 (en) | 2007-12-04 |
| EP1535907A1 (en) | 2005-06-01 |
| CA2496623C (en) | 2008-02-12 |
| HK1082497A1 (en) | 2006-06-09 |
| CN1310885C (zh) | 2007-04-18 |
| AU2003261748A1 (en) | 2004-03-19 |
| JP3746063B2 (ja) | 2006-02-15 |
| MXPA05002253A (es) | 2005-06-08 |
| US20060106087A1 (en) | 2006-05-18 |
| ECSP055708A (es) | 2005-08-11 |
| WO2004020407A1 (ja) | 2004-03-11 |
| KR20050059094A (ko) | 2005-06-17 |
| NO20050867L (no) | 2005-02-18 |
| KR100582141B1 (ko) | 2006-05-22 |
| AU2003261748B2 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1082497A1 (en) | Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative | |
| HUS1400037I1 (hu) | Új 2-piridiletilbenzamid származékok | |
| ZA200500294B (en) | Novel 2-pyridylethylbenzamide derivative | |
| AP1850A (en) | Spiroindolineplperidine derivatives | |
| EG24050A (en) | Heterocylocarboxamide derivatives | |
| AU2003211362A1 (en) | N-hydroxycarboxamide derivative | |
| AU2003201850A1 (en) | N-alkylsulfonyl-substituted amide derivatives | |
| AU2003202924A1 (en) | Variation of neural-stimulation parameters | |
| HK1077068A1 (en) | Azolidinone-vinyl fused-benzene derivatives | |
| EP1522540A4 (en) | AZAARENE DERIVATIVES | |
| AU2003268687A1 (en) | Novel salt of 2-acylaminothiazole derivative | |
| AU2002314566A8 (en) | Novel curcumin derivatives | |
| EP1498420A4 (en) | phospholipid | |
| AU2003222659A8 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
| AU2003231370A1 (en) | Amide derivatives | |
| AU2003229459A1 (en) | Methods of using thiazolidinedithione derivatives | |
| AU2003235889A1 (en) | Amide derivatives | |
| EP1531854A4 (en) | O-DERIVATED NOCATHIACIN DERIVATIVES | |
| AU2003266714A8 (en) | Phospholipid derivative | |
| GB0213488D0 (en) | 2-Naphthamide derivatives | |
| AU2002359458A1 (en) | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | |
| AU2003261875A1 (en) | Amine derivative | |
| EP1486485A4 (en) | NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS | |
| AU2003291021A1 (en) | Arylpyridine compounds | |
| AU2003243397A8 (en) | Homo-camptothecin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |